Researchers from NCI and their collaborators have discovered that people of European and African ancestries who were hospitalized for COVID-19 are more likely to carry a particular combination of genetic variants in a gene known as OAS1 than patients with mild disease who were not hospitalized.
COVID-19 was the third leading cause of death in the United States between March 2020 and October 2021, according to an analysis of national death certificate data by researchers at NCI.
NCI is moving forward with a plan to evaluate multi-cancer early detection tests, a technology that is rapidly making inroads into the healthcare system.
The NCI Board of Scientific Advisors unanimously approved eight new concepts and nine reissued concepts at a meeting June 13-15.
As she was interviewing for the director’s job at the George Washington Cancer Center, Julie E. Bauman was asked what her biggest fear would be.
NCI and Cancer Research UK have awarded $100 million in total funding through the Cancer Grand Challenges program, supporting research into solid tumors in children, cachexia, extrachromosomal DNA, and tumor development.
In the next phase of the Cancer Moonshot, NCI will focus on investing in the development and testing of new modalities, including multi-cancer early detection assays, and fostering diversity in oncology, NCI Acting Director Douglas R. Lowy said at a joint meeting of the Board Of Scientific Advisors and the National Cancer Advisory Board.
Before the results of the ANal Cancer/HSIL Outcomes Research (ANCHOR) study became available earlier this week, there was no clear reason to screen for the anal cancer precursor, anal high-grade squamous intraepithelial lesions (HSIL).
NCI must make a bigger investment in new cancer therapies and expand the clinical trials system that tests them, the institute’s Acting Director Douglas Lowy said in his remarks at the American Society of Clinical Oncology annual meeting June 4.
NCI has truncated the just-renewed five-year Cancer Center Support Grant held by Wake Forest Baptist Comprehensive Cancer Center as that institution undergoes a bumpy transition of leadership—in the midst of a challenging integration with Atrium Health Levine Cancer Institute.
